Fehlings, Michael
Jhunjhunwala, Suchit
Kowanetz, Marcin
O’Gorman, William E.
Hegde, Priti S.
Sumatoh, Hermi
Lee, Boon Heng
Nardin, Alessandra
Becht, Etienne
Flynn, Susan
Ballinger, Marcus
Newell, Evan W.
Yadav, Mahesh
Article History
Received: 23 April 2019
Accepted: 25 July 2019
First Online: 12 September 2019
Ethics approval and consent to participate
: Participants provided informed consent to participate in the study. The trial was sponsored by Genentech, Inc., a member of the Roche Group, which provided the study drug, atezolizumab. The protocols and their amendments were approved by the relevant institutional review boards or ethics committees, and all participants provided written informed consent. The clinical trial was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice: ExternalRef removed: NCT01903993 (ExternalRef removed).
: All authors read the paper and concur with the submission.
: M.Y., S.J., B.O., M.B., S.F. and P.H. are employees and stockholders of Genentech/Roche.A.N., M.F., H.S. and B.H.L. are employees and stockholders of immunoSCAPE Pte Ltd. A.N. and E. N. are stockholders and Board Directors of immunoSCAPE Pte Ltd.